Recruiting Patient Preference for Subcutaneous vs. Intravenous Immune Therapy NCT07223424 Conditions Adenocarcinoma, Adenocarcinoma Of Esophagus, Bronchial Neoplasms, +70 more Locations UPMC Hillman Cancer Center — Pittsburgh, Pennsylvania, United States View Trial Details
Recruiting Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer NCT07352280 Conditions Colo-rectal Cancer (dMMR/MSI-H CRC), Colonic Diseases, Colonic Neoplasms, +9 more Locations Cancer Institute and Hospital, Chinese Academy of Medical Sciences — Beijing, Undefined, China View Trial Details
